Derivation of a peripheral blood-based transcriptomic risk score for extrapulmonary sarcoidosis.
Sarcoidosis vasculitis and diffuse lung diseases · 30.09.2026 · 43 (3) · 18384-18384
DOI: 10.36141/svdld.2026.18384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 30.09.2026. Verfasst von Gargi Mishra und 7 weiteren Autor:innen. Beteiligte Einrichtung: SUNY Upstate Medical University. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Extrapulmonary sarcoidosis can be identified in many tissues but as an unpredictable display in an already rare disease, has not been methodically examined. We sought to identify gene-expression differences in blood and derive a transcriptomic risk score (TRS) to predict extrapulmonary manifestations of sarcoidosis. METHODS: We used RNA sequencing data from the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study and a cohort from our institution. We performed differential expression mega-analysis as well as pathway enrichment and cell-type deconvolution comparing individuals with pulmonary-only sarcoidosis to those with extrapulmonary sarcoidosis. In addition, we deployed supervised learning models to develop the TRS to distinguish extrapulmonary sarcoidosis from pulmonary-only disease. RESULTS: We identified 594 genes that met the nominal significance threshold for differential expression. In the local cohort, we found that individuals with extrapulmonary sarcoidosis had a significantly lower proportion of estimated naïve and memory B cells. The TRS had moderate predictive ability for extrapulmonary sarcoidosis in the held-out testing sample (AUC 0.72) but only modest predictive ability (AUC 0.58) in the independent dataset. CONCLUSION: Our study demonstrates that a TRS derived from blood-based transcriptomics is able to distinguish between individuals with pulmonary-only and extrapulmonary sarcoidosis. The TRS is also comprised of biologically relevant genes, including several T cell receptor alpha subunit genes. Future studies are needed to prospectively validate our findings and potentially expand their use to identify precision treatments for individuals with extrapulmonary sarcoidosis.
Schlagwörter
Autor:innen und Institutionen
- SUNY Upstate Medical University.
- Brigham and Women's Hospital.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Mishra, G., Razavi, A., Hess, J. L., Ecal, K., Hersh, C. P., Glatt, S. J., Sah, B., & Ghosh, A. J. (2026). Derivation of a peripheral blood-based transcriptomic risk score for extrapulmonary sarcoidosis. Sarcoidosis vasculitis and diffuse lung diseases, 43(3), 18384-18384. https://doi.org/10.36141/svdld.2026.18384
Vancouver
Mishra G, Razavi A, Hess JL, Ecal K, Hersh CP, Glatt SJ, et al. Derivation of a peripheral blood-based transcriptomic risk score for extrapulmonary sarcoidosis. Sarcoidosis vasculitis and diffuse lung diseases. 2026;43(3):18384-18384. doi:10.36141/svdld.2026.18384
BibTeX
@article{Mishra2026,
author = {Mishra, Gargi and Razavi, Ali and Hess, Jonathan L and Ecal, Kathleen and Hersh, Craig P and Glatt, Stephen J and Sah, Birendra and Ghosh, Auyon J},
title = {Derivation of a peripheral blood-based transcriptomic risk score for extrapulmonary sarcoidosis},
journal = {Sarcoidosis vasculitis and diffuse lung diseases},
year = {2026},
volume = {43},
number = {3},
pages = {18384--18384},
doi = {10.36141/svdld.2026.18384}
}
EUVIMED